knownwell’s Post

-Eli Lilly's Get Better campaign seeks to challenge misconceptions and foster dialogue about obesity as a medical condition, unveiling two thought-provoking films, "Shame" and "Big Night." -"Shame" and "Big Night" films spotlight Lilly's dedication to patient care and emphasize the importance of addressing obesity without judgment or stigma, timed strategically to spark conversations during Obesity Care Week and awards season. -Jennifer Oleksiw, Lilly's Global Chief Customer Officer, underscores the company's commitment to patient safety and responsible medication use, advocating for healthcare professional guidance in the treatment of obesity. To know more, read the full article on #theenterprise #GetBetterCampaign #ObesityAwareness #EndWeightStigma #PatientCare #HealthEquity#globalbusiness #theenterprisenews #followformore #global #finance

Does improving the patient experience with empathic care also lead to better health outcomes? To answer the question, Helen Riess, M.D. a renowned neuroscientist and Founder of Empathetic, with her team at Harvard Medical School, embarked on a research project. Their focus was on conducting a systematic review and meta-analyses of medical literature published since 1990, which explored the connection between relationship factors and enhanced health outcomes. The findings were remarkable! Study has found that strong relationship factors between physicians and patients led to significant improvements in many common conditions such as obesity, asthma, lung infection, as well as diabetics and hypotension.  In her book “Empathy effect”, Dr. Riess says: “By examining relationship factors we can now confidently say that How physicians treat patients is as important as What they treat”  This emphasizes the need for physicians to listen to "the whole person" rather than focusing solely on the immediate complaint. Such an approach fosters a deeper connection, allowing the caregiver to fully understand and empathize with the patient's experiences. #Healthcare #EmpathyInCare #PatientCare #HarvardMedicalSchool #TheEmpathyEffect #HealthOutcomes #Empathetic #PatientExperience

In case you missed last week's video of In The Know With Nina - stay in the know with our podcast! What's in this episode? Dr. Nina Crowley, PhD, RDN, LD and and Immediate Past President of the American Society For Metabolic And Bariatric Surgery Integrated Health Section, Nate Sann NP, discuss the shift towards a multimodal treatment approach in obesity care, emphasizing collaboration among healthcare providers and personalized treatment options. They highlight the importance of advocacy, research, and education to improve access to care and reduce the stigma surrounding obesity. The focus is on patient-centered care, acknowledging the importance of understanding patients' goals and desires while offering a range of treatment options including nutrition, medication, behavioral health, and surgical interventions. #seca #podcast #ITKWN #mBCA #bodycomposition #bodycomp #healthcare #ASMBS #weight #weightmanagement #treatment

On this episode of the Bright Spots in Healthcare Podcast, Dr. Timothy Law, Chief Medical Officer at Highmark Health, spoke with Eric Glazer about GLP-1s, a class of medications used for obesity management. Dr. Law stressed on the importance of these medications, despite their high cost, considering the profound impact diabetes and obesity have on human life and the downstream cost of care. He argued that the cost of these medications is insignificant when compared to the astronomical expense of managing the health complications arising from these conditions. However, he emphasized that like any other medicine, GLP-1s should be used intelligently and not in isolation, but as part of a comprehensive lifestyle modification. Healthcare, he concluded, is about smart choices. Repost this video if you believe in a comprehensive approach to treating diabetes and obesity. Learn from Dr. Timothy Law how smart use of medicine and lifestyle modification can save lives and reduce costs. #DiabetesTreatment #ObesityManagement #LifestyleModification

Looking forward to being a part of this webinar. #obesity All About Obesity CIC

27 speakers engaged with participants over 14 sessions, with interactive panel discussions covering some of the hottest topics in diabetes care. Coming from a range of backgrounds, speakers and participants shared insights to improve outreach, diagnosis and treatment among Black communities. In addition to clinical education, the programme included policy-oriented and strategic topics, such as the creation and scaling-up of culturally-appropriate diabetes and obesity programmes. We designed sessions to be both informative and interactive, with audience participation. In the post-event survey, participants gave the relevance of the programme an average rating of 4.8 out of 5. Find out why by downloading the report here: https://lnkd.in/gyvA7W3g Want to attend our 2024 UK Forum? Early bird tickets are available for a limited time: https://lnkd.in/eRnMm5NS #EquityNow Disclaimer: The 2024 UK Forum is sponsored by Eli Lilly and Company, A. Menarini Farmaceutica Internazionale SRL, and AgaMatrix who have had no input into the topics discussed or the selection of speakers. #healthcare #health #HealthcareProfessional #healthcareprofessionals #diabetescare #diabeteshealth #diabeteseducation Bernadette Adeyileka-Tracz Greg Tracz Joan St John Evelyn Mensah Barbara Hudson Meera Ladwa Dr Raymond Ladele MBBS, MSc, MRCGP, PGDip Steven Parks Tolu Shonibare

In the ever-evolving landscape of healthcare, understanding patient access to specialized care is paramount. As part of our commitment to fostering meaningful discussions and solutions in this realm, we're proud to share that our COO, Rohit Rustagi, will be presenting his insights at the 2023 World Obesity Conference in Boston, MA this coming week! Rohit's talk will delve into the intricacies of regional disparities in obesity care access, focusing on wait times across top U.S. hospitals. This topic is not just about numbers, but about real people waiting for essential medical attention. Our goal is to: 1) Help audiences grasp the current barriers patients face when seeking obesity treatment, 2) Explore innovative strategies to enhance patient access and reduce wait times, and 3) Contemplate on the urgent necessity for a broader understanding and approach to obesity medicine and the role of health systems in addressing it.  🔗 Link to the abstract in comments!

If you didn't catch the Youtube interview, you can still stay In The Know through our podcast! In this thought-provoking episode, Dr. Nina Crowley, seca’s Professional Affiliations and Education Manager talks with Dr. Sylvia Gonsahn-Bollie about the recent discussion at the American Medical Association (AMA) about the challenges and use of Body Mass Index (BMI) as a sole indicator of health and weight. Dr. Bollie advocates for a more personalized and comprehensive approach to obesity care. They highlight the limitations of BMI, including its biases and failure to account for individual differences and discuss alternative measurements such as adjusted BMI, waist circumference, and body composition, which provide a more accurate assessment of metabolic health and disease risk. The conversation also explores the need for education and resources to support healthcare professionals in implementing these new approaches. Overall, the conversation emphasizes the importance of reevaluating traditional metrics and embracing individualized strategies for a holistic understanding of weight and health. #seca #bodycomposition #mbca #medicalbodycomposition #BIA #healthcare #healthcaretech

In my discussion with Nick Meyer, MD we discuss the concerning trend of overusing GLP-1 receptor agonists—drugs designed for diabetes treatment—now being touted as a quick fix for weight loss. Without question there is role for these in medical treatment of diabetes and morbid obesity, but the real dilemma is in clarifying the ultimate indications! - The intense push to repurpose these medications for weight management in almost “all” cases is alarming given the serious side effect profiles that are coming to light - Also potentially alarming is the wide use in the pediatric population now approved to age 12 but being studied for approval for those 6 years and over. - Should there be pushback against industry overreach? - In this episode while acknowledging that there is a definite role for these medications in carefully selected patients, we highlight the serious risks and side effects that are somewhat glossed in a frantic rush to market GLP-1s as a quick weight loss solution. This discussion is a call to action for healthcare professionals and an eye-opener for the public, urging a critical examination of the industry’s influence on our health choices. 💡 We’re sparking a crucial debate on health, ethics, and the future of weight management. Watch now to arm yourself with knowledge and join us in questioning the status quo. Let’s demand better standards and transparency in our journey toward genuine wellness. Here is the full episode https://lnkd.in/eNRJeTbs Follow us 👍 #EthicalHealthcare #GLP1controversy #InformedChoice #DebateHealth #RechargingTheHumanBattery #Podcats #healthcare #Diet #humanity #People #Netwoking

Ozempic, Wegovy, Mounjaro - these meds are conversation starters for a reason. But are we having the right conversations about them? And for the right reasons? Their effectiveness in treating diabetes and chronic obesity is obvious, but I’m challenging you to take a step back as there's much more to consider - like costs, post-treatment weight gain, side effects, and the lifestyle changes that are prescribed alongside these medications. Omada Health’s Chief Medical Officer Carolyn Bradner Jasik, MD is covering all these considerations in a video blog series discussing our clinical stance on GLP-1s. Check it out the first video below, and see the whole series here: https://lnkd.in/gFPVhcac